Novavax, Inc. was granted conditional marketing authorization (CMA) for Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted)  by the European Commission for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The authorization follows the EMA Committee for Medicinal Products for Human Use recommendation.   The EMA opinion and related EC decision is based on the totality of preclinical, manufacturing and clinical trial data submitted for review...